Veronica Mulenga

1.8k total citations
39 papers, 1.2k citations indexed

About

Veronica Mulenga is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Veronica Mulenga has authored 39 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Infectious Diseases, 18 papers in Virology and 10 papers in Epidemiology. Recurrent topics in Veronica Mulenga's work include HIV/AIDS Research and Interventions (25 papers), HIV/AIDS drug development and treatment (24 papers) and HIV Research and Treatment (18 papers). Veronica Mulenga is often cited by papers focused on HIV/AIDS Research and Interventions (25 papers), HIV/AIDS drug development and treatment (24 papers) and HIV Research and Treatment (18 papers). Veronica Mulenga collaborates with scholars based in Zambia, United Kingdom and Uganda. Veronica Mulenga's co-authors include Diana M. Gibb, Chifumbe Chintu, Fredrick Sinyinza, Andrew Nunn, Kennedy Lishimpi, A Sarah Walker, A. Sarah Walker, Alimuddin Zumla, Stephen H. Gillespie and David M. Burger and has published in prestigious journals such as The Lancet, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Veronica Mulenga

37 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Veronica Mulenga Zambia	18	893	380	364	216	200	39	1.2k
John Idoko Nigeria	21	771 0.9×	625 1.6×	260 0.7×	120 0.6×	155 0.8×	78	1.3k
Elizabeth Spooner South Africa	10	735 0.8×	554 1.5×	201 0.6×	113 0.5×	212 1.1×	24	1.0k
Raziya Bobat South Africa	16	893 1.0×	395 1.0×	416 1.1×	130 0.6×	260 1.3×	48	1.3k
Ersilia Buonomo Italy	16	628 0.7×	272 0.7×	158 0.4×	144 0.7×	135 0.7×	78	956
Elizabeth Maleche‐Obimbo Kenya	20	764 0.9×	526 1.4×	322 0.9×	109 0.5×	101 0.5×	95	1.1k
James Ndirangu South Africa	15	464 0.5×	233 0.6×	145 0.4×	190 0.9×	159 0.8×	26	798
Erik van Widenfelt United States	18	852 1.0×	266 0.7×	531 1.5×	113 0.5×	145 0.7×	28	1.1k
Lloyd Mulenga Zambia	23	1.2k 1.3×	521 1.4×	347 1.0×	145 0.7×	62 0.3×	89	1.5k
John Lule Uganda	9	596 0.7×	360 0.9×	193 0.5×	209 1.0×	147 0.7×	11	908
Elisabeth Szumilin France	23	1.6k 1.8×	706 1.9×	743 2.0×	232 1.1×	52 0.3×	48	1.8k

Countries citing papers authored by Veronica Mulenga

Since Specialization

Citations

This map shows the geographic impact of Veronica Mulenga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veronica Mulenga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veronica Mulenga more than expected).

Fields of papers citing papers by Veronica Mulenga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Veronica Mulenga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veronica Mulenga. The network helps show where Veronica Mulenga may publish in the future.

Co-authorship network of co-authors of Veronica Mulenga

This figure shows the co-authorship network connecting the top 25 collaborators of Veronica Mulenga. A scholar is included among the top collaborators of Veronica Mulenga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Veronica Mulenga. Veronica Mulenga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Waalewijn, Hylke, Alexander J. Szubert, Veronica Mulenga, et al.. (2024). Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV. Journal of Antimicrobial Chemotherapy. 79(11). 2990–2998. 2 indexed citations

Chabala, Chishala, Clémentine Roucher, Veronica Mulenga, et al.. (2024). Development of tuberculosis treatment decision algorithms in children below 5 years hospitalised with severe acute malnutrition in Zambia and Uganda: a prospective diagnostic cohort study. EClinicalMedicine. 73. 102688–102688. 4 indexed citations

Waalewijn, Hylke, Alexander J. Szubert, Roeland E. Wasmann, et al.. (2023). First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial. Clinical Infectious Diseases. 77(6). 875–882. 7 indexed citations

Waalewijn, Hylke, Alexander J. Szubert, Chishala Chabala, et al.. (2023). Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial. Clinical Infectious Diseases. 77(9). 1312–1317. 3 indexed citations

Turner, Rebecca, Anna Turkova, Alasdair Bamford, et al.. (2022). Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial. BMC Medical Research Methodology. 22(1). 49–49. 5 indexed citations

Chabala, Chishala, Anna Turkova, Anneke C. Hesseling, et al.. (2021). Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization–Recommended Weight Band Doses and Formulations. Clinical Infectious Diseases. 74(10). 1767–1775. 17 indexed citations

Vessière, Aurélia, Delphine Gabillard, Laurence Borand, et al.. (2021). Impact of systematic early tuberculosis detection using Xpert MTB/RIF Ultra in children with severe pneumonia in high tuberculosis burden countries (TB-Speed pneumonia): a stepped wedge cluster randomized trial. BMC Pediatrics. 21(1). 136–136. 6 indexed citations

Abongomera, George, Adrian Cook, Victor Musiime, et al.. (2016). Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa. AIDS and Behavior. 21(2). 441–449. 8 indexed citations

Cook, Adrian, Lubbe Wiesner, Veronica Mulenga, et al.. (2016). Effect of diurnal variation,CYP2B6genotype and age on the pharmacokinetics of nevirapine in African children. Journal of Antimicrobial Chemotherapy. 72(1). 190–199. 8 indexed citations

10.

Mulenga, Veronica, Victor Musiime, Adeodata Kekitiinwa, et al.. (2015). Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. The Lancet Infectious Diseases. 16(2). 169–179. 32 indexed citations

11.

Mulenga, Veronica, Chipepo Kankasa, Margaret J. Thomason, et al.. (2012). Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets. AIDS. 26(14). 1795–1800. 14 indexed citations

12.

Kenny, Julia, et al.. (2012). The needs for HIV treatment and care of children, adolescents, pregnant women and older people in low-income and middle-income countries. AIDS. 26(Supplement 2). S105–S116. 15 indexed citations

13.

Prendergast, Andrew J., Martina Penazzato, Mark F. Cotton, et al.. (2012). Treatment of Young Children with HIV Infection: Using Evidence to Inform Policymakers. PLoS Medicine. 9(7). e1001273–e1001273. 35 indexed citations

14.

Mbisa, Jean L., Ravindra K. Gupta, Veronica Mulenga, et al.. (2011). The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains. Retrovirology. 8(1). 31–31. 10 indexed citations

15.

Mulenga, Veronica, et al.. (2011). Diarrhea is a Major killer of Children with Severe Acute Malnutrition Admitted to Inpatient Set-up in Lusaka, Zambia. Nutrition Journal. 10(1). 110–110. 125 indexed citations

16.

Haberer, Jessica E., Adrian Cook, A Sarah Walker, et al.. (2011). Excellent Adherence to Antiretrovirals in HIV+ Zambian Children Is Compromised by Disrupted Routine, HIV Nondisclosure, and Paradoxical Income Effects. PLoS ONE. 6(4). e18505–e18505. 101 indexed citations

17.

Gupta, Ravindra K., Deborah Ford, Veronica Mulenga, et al.. (2010). Drug Resistance in Human Immunodeficiency Virus Type-1 Infected Zambian Children Using Adult Fixed Dose Combination Stavudine, Lamivudine, and Nevirapine. The Pediatric Infectious Disease Journal. 29(8). e57–e62. 22 indexed citations

18.

Walker, A Sarah, Deborah Ford, Veronica Mulenga, et al.. (2008). Adherence to Both Cotrimoxazole and Placebo is Associated with Improved Survival Among HIV-Infected Zambian Children. AIDS and Behavior. 13(1). 33–41. 12 indexed citations

19.

Walker, A Sarah, Veronica Mulenga, Fredrick Sinyinza, et al.. (2006). Determinants of Survival Without Antiretroviral Therapy After Infancy in HIV-1-Infected Zambian Children in the CHAP Trial. JAIDS Journal of Acquired Immune Deficiency Syndromes. 42(5). 637–645. 60 indexed citations

20.

Chintu, Chifumbe, AS Walker, Veronica Mulenga, et al.. (2004). Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. The Lancet. 364(9448). 1865–1871. 280 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact